Champions Oncology, Inc. (CSBR)

NASDAQ: CSBR · IEX Real-Time Price · USD
5.58
-0.08 (-1.41%)
Mar 1, 2024, 4:00 PM EST - Market closed
-1.41%
Market Cap 75.85M
Revenue (ttm) 49.98M
Net Income (ttm) -9.64M
Shares Out 13.59M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE 22.88
Dividend n/a
Ex-Dividend Date n/a
Volume 4,288
Open 5.65
Previous Close 5.66
Day's Range 5.55 - 5.65
52-Week Range 3.95 - 7.32
Beta 0.39
Analysts Strong Buy
Price Target 7.50 (+34.41%)
Earnings Date Mar 13, 2024

About CSBR

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 1986
Employees 230
Stock Exchange NASDAQ
Ticker Symbol CSBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CSBR stock is "Strong Buy" and the 12-month stock price forecast is $7.5.

Price Target
$7.5
(34.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Champions Oncology Reports Quarterly Revenue of $11.6 Million

HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today ...

2 months ago - Accesswire

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023

HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report it...

3 months ago - Accesswire

Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification

HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announc...

4 months ago - Accesswire

Champions Oncology Announces the Addition of Brady Davis as President

HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has app...

4 months ago - Accesswire

Champions Oncology Reports Quarterly Revenue of $12.6 Million

HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven ...

6 months ago - Accesswire

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023

HACKENSACK, NJ / ACCESSWIRE / September 11, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmac...

6 months ago - Accesswire

Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023

HACKENSACK, NJ / ACCESSWIRE / August 22, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks-of...

6 months ago - Accesswire

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solution...

7 months ago - Accesswire

Champions Oncology Reports Quarterly Revenue of $13.1 Million

Record Annual Revenue of $53.9 Million HACKENSACK, NJ / ACCESSWIRE / July 24, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug disco...

7 months ago - Accesswire

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-phe...

8 months ago - Accesswire

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative ...

11 months ago - Accesswire

Champions Oncology Announces $5M Stock Repurchase Program

HACKENSACK, NJ / ACCESSWIRE / April 5, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-phe...

11 months ago - Accesswire

Champions Oncology Reports Quarterly Revenue of $12.8 Million

HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven phar...

1 year ago - Accesswire

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven phar...

1 year ago - Accesswire

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven p...

1 year ago - Accesswire

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-...

1 year ago - Accesswire

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven p...

1 year ago - Accesswire

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven p...

1 year ago - Accesswire

Champions Oncology Reports Quarterly Revenue of $12.9 Million

Record Annual Revenue of $49.1 Million HACKENSACK, NJ / ACCESSWIRE / July 21, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug disco...

1 year ago - Accesswire

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-phe...

1 year ago - Accesswire

Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative ...

1 year ago - Accesswire

Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo

HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmac...

1 year ago - Accesswire

Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven phar...

2 years ago - Accesswire

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-ph...

2 years ago - Accesswire

Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors

HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven p...

2 years ago - Accesswire